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Background: The contribution of glycemic variability to macrovascular complications remains unclear. We therefore
investigated the association between glycemic variability and cervical and/or intracranial atherosclerosis in Chinese
type 2 diabetic patients.
Methods: We conducted a cross-sectional study in 216 type 2 diabetic patients with a hemoglobin A1c of 8.3 ±
1.7% and a median diabetes duration of 9.0 years. The standard deviation of blood glucose values (SDBG) and the
mean amplitude of glycemic excursion (MAGE) were calculated from continuous glucose monitoring system data
for assessing glycemic variability while 24h mean blood glucose (MBG) was calculated for measuring overall blood
glucose level. Magnetic resonance angiography (MRA) was used to detect cervical and/or intracranial plaque, and
ultrasonography was used to quantify carotid intima-media thickness (IMT) as an index of subclinical atherosclerosis.
Results: One hundred and fifty-three patients (70.8%) presented with cervical and/or intracranial lesions on MRA
among 216 patients in the study. Elder age, increased systolic blood pressure, increased MBG and elevated low
density lipoprotein cholesterol were independent contributors to plaque formation. In patients without stenosis
(n = 63), SDBG (r = 0.412, P = 0.001) and MAGE (r = 0.365, P = 0.005) were both correlated with carotid IMT and these
relationships remained significant in multiple linear regression analysis (multiple R2 = 0.314 for the model including
SDBG and multiple R2 = 0.268 for the model including MAGE). However, SDBG and MAGE were not significantly
different among patients with different stenosis degrees.
Conclusions: Glycemic variability is associated with subclinical atherosclerosis in Chinese type 2 diabetic patients.
Keywords: Glycemic variability, Type 2 diabetes, Atherosclerosis, Intima-media thickness, Magnetic resonance
angiography.Background
Macrovascular diseases such as coronary artery disease
and cerebrovascular disease are major complications of
type 2 diabetes. Previous studies have shown the associ-
ation between averaged mean levels of glycemia and
macrovascular complications [1,2]. Meanwhile, several
lines of evidence have raised the possibility that glycemic
variability, which includes both upward and downward
acute glucose changes, is another important component of
dysglycemia [3]. Glycemic variability can have deleterious* Correspondence: wpjia@sjtu.edu.cn
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reproduction in any medium, provided the oreffects on the development and progression of macrovas-
cular complication through oxidative stress and endothe-
lial dysfunction [4,5]. With the emergence of continuous
glucose monitoring (CGM) technology, the assessment of
glycemic variability is now much less cumbersome. How-
ever, the exact role of glucose variability in the develop-
ment of atherosclerosis remains unclear.
Atherosclerosis is a complex multifactorial disease,
often preceding the development of diabetic macrovas-
cular complications. Carotid intima-media thickness
(IMT), measured noninvasively by ultrasonography, is
accepted as an indicator of subclinical atherosclerosis,
and has been reported to be directly associated with an
increased risk of cardiovascular and cerebrovascular dis-
eases [6]. Furthermore, in terms of defining the presence. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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resonance angiography (3D-TOF-MRA) and contrast-
enhanced magnetic resonance angiography (CEMRA)
are reported to be more informative than ultrasonog-
raphy [7,8]. To gain insight into the role of glycemic
variability in the different stages of atherosclerosis, we
used both ultrasonography and MRA to determine pre-
clinical atherosclerosis and plaque formation. The aims
of this study were: (i) to investigate the prevalence of
atherosclerotic plaque by examining the cervical and
intracranial arteries using MRA in Chinese type 2 dia-
betic patients; and (ii) to explore the role of glycemic
variability in both the subclinical stage and plaque for-
mation stage of atherosclerosis in this population.
Methods
Study populations
The study was carried out over a period of 12 months be-
tween 1 January 2008 and 31 December 2008. We included
216 type 2 diabetic patients who consulted for complica-
tions screening at the Department of Endocrinology and
Metabolism in our hospital on an annual basis. Type 2 dia-
betes was diagnosed according to 1999 World Health
Organization (WHO) criteria [9]. Eligibility was based on a
stable therapeutic regimen with oral hypoglycemic agents
and/or insulin for the previous 3 months. Exclusion criteria
included recent acute complications such as diabetic ketoa-
cidosis and hyperglycemic hyperosmolar state, severe and
recurrent hypoglycemic events in the previous 3 months, a
history of hepatic or renal impairment, or of other diseases
that can influence glucose metabolism, including recent
acute cerebral stroke, acute myocardial infarction, malnu-
trition, and cancers. In addition, claustrophobic patients,
and patients with valvular prostheses, vascular clips, car-
diac pacemakers, or other implanted devices sensitive to
strong magnetic fields, were also excluded from the study.
The original study received approval from the Ethics Com-
mittees of Shanghai Jiao Tong University Affiliated Sixth
People’s Hospital in accordance with the principle of the
Helsinki Declaration. Written informed consent was
obtained from each participant.
CGM parameters
Subcutaneous interstitial glucose was monitored con-
tinuously for 3 consecutive days using a retrospective
CGM system (Medtronic Inc, Northridge, CA, USA).
The sensor of the CGM system was inserted on day 0
and removed after 72 h; this generated a daily record of
288 continuous sensor values. A minimum of four capil-
lary blood glucose readings per day, as measured by a
SureStep blood glucose meter (LifeScan, Milpitas, CA,
USA), were entered into the CGM system for calibra-
tion. The 24h mean blood glucose (MBG) level was cal-
culated from the 288 consecutive sensor readings over a24h period. The 24h MBG and intraday glycemic vari-
ability were based on the mean values taken on days 1
and 2. Intraday glycemic variability parameters include
the standard deviation of blood glucose values (SDBG)
[10] and the mean amplitude of glycemic excursions
(MAGE) [11]. MAGE was calculated by measuring the
arithmetic mean of the differences between consecutive
peaks and nadirs; measurement in the peak-to-nadir or
nadir-to-peak direction was determined by the first
qualifying excursion; only excursions of more than 1 SD
of the mean glycemic values were considered because
MAGE was designed to quantify only major swings of
glycemia instead of minor ones. All patients wore
blinded CGM system and received the same therapy as
before admission. The CGM monitoring was performed
in the hospital and the mean CGM period ± SD was 71
± 3h. The reference values for CGM system in Chinese
population have been reported elsewhere [12,13].
Patients were instructed to adhere to a standard diet
during the three-day period of CGM sensor monitoring.
The diet was designed to ensure a total daily caloric in-
take of 25 kcal/kg/day, with 55% of calories coming from
carbohydrates, 17% from proteins, and 28% from fats.
Written instructions were provided to achieve the ap-
propriate caloric content and to guide the consumption
times, which included breakfast (20% of daily calories,
06:30–07:30), lunch (40%, 11:30–12:30), and dinner
(40%, 18:00–19:00).
Cervical and intracranial magnetic resonance angiography
(MRA) examination
All MRA examinations were performed using a 3.0 tesla
MR system (Achieva, Philips Medical Systems). Intracra-
nial MRA was performed using a 3D-TOF-MRA se-
quence with an 8-channel head coil or a 16-channel
craniocervical joint coil. The 3D-TOF-MRA was
obtained with repetition time/echo time (TR/TE) 30/3.2
msec, flip angle 20°, field of view (FOV) 250 × 220 mm,
four slabs (180 slices), 1.2 mm slice thickness, matrix
1024 × 1024 and an acquisition time of 8 min 56 s. The
acquired images were then transferred to a separate
workstation (View Forum; Philips Medical Systems) to
obtain both the maximum-intensity projection (MIP)
and volume rendering (VR) images. Cervical MRA was
performed using the high spatial resolution CEMRA se-
quence with a 16-channel craniocervical joint coil. Para-
meters were as follows: a 4.7/1.79 msec TR/TE; 27° flip
angle; 320 × 320 mm FOV; 150 slices; 1.0 mm slice
thickness, matrix 704 × 704 and an acquisition time of 1
min 27 s. A 1 ml bolus dose of gadolinium (0.5 mol/l,
Magnevist; Bayer Health Care Pharmaceuticals) was
administered intravenously at a flow rate of 2.5 ml/s by
a power injector, followed by 21 ml of saline flush to
measure the time taken for the gadolinium to reach the
Mo et al. Cardiovascular Diabetology 2013, 12:15 Page 3 of 9
http://www.cardiab.com/content/12/1/15aortic arch. Subsequently, 19 ml of gadolinium was
injected at the same rate. The average scanning delay
time was 13 s (11–19 s).
The intracranial portion of the internal carotid artery
(I-ICA), the anterior, middle, and posterior cerebral ar-
teries (ACA, MCA and PCA), the intracranial vertebral
artery (I-VA), and the basilar artery (BA) were evaluated
by intracranial MRA. The common carotid artery
(CCA), the extracranial portion of the internal carotid
artery (E-ICA), the extracranial vertebral artery (E-VA),
the external carotid artery (ECA), and the subclavian ar-
tery (SUB) were evaluated by cervical MRA. All MRA
findings were reviewed by two investigators who were
blind to patient clinical data. The severity of arterial
stenosis was rated into five grades depending on the nar-
rowing of the arteries: without any reduction of arterial
diameter; <10% reduction of arterial diameter; 10–50%
reduction; 51–99% reduction; and complete occlusion
[14]. If stenosis severity for a given artery was different
between the right and left sides, the side with more se-
vere stenosis was used for grade assignment and ana-
lysis. When two or more stenoses were detected in
different arteries, the most severe arterial stenosis grade
was used for patient classification.
Ultrasound measurement
Common carotid arteries were assessed using a high
resolution B-mode ultrasound (Sequoia 512, Siemens,
Germany) equipped with a 10 MHz probe, as previously
described [15]. A single sonographer blind to patient
clinical characteristics measured bilateral carotid arter-
ies. Both common carotid arteries were scanned from
proximal to distal in relation to the bifurcation. IMT
was measured at the far wall of both common carotid
arteries, approximately 1 cm proximal to the carotid
bulb. The carotid IMT value was calculated as the mean
of the maximal IMT of each carotid artery.
Anthropometric and biochemical measurements
Each patient had a physical examination including mea-
surements of height, weight, and blood pressure in an
air-conditioned, quiet room. We calculated body mass
index (BMI) as weight (kg) divided by squared height
(m). The blood pressure was measured indirectly using a
mercury sphygmomanometer. Sitting blood pressure was
measured after 5-min rest with a blood pressure cuff ap-
propriately sized to arm circumference and placed on
the subject’s non-dominant arm. The average of three
measurements at two minute intervals was used for the
analysis. Smoking status was based on an interview. Sub-
jects were classified as nonsmokers or current smokers.
On a separate day from 3-day CGM measurement, ven-
ous blood sample was drawn on 6 AM after a 10 hour
overnight fasting to test the biochemical measurements.Hepatic biomarkers, including alanine aminotransferase
(ALT), aspartate aminotransferase (AST); renal function
biomarkers including blood urea nitrogen (BUN), plasma
creatinine, and uric acid; triglycerides (TG), total choles-
terol (TC), high density lipoprotein cholesterol (HDL-C),
and low density lipoprotein cholesterol (LDL-C), were
determined by standard enzymatic methods using a bio-
chemical analyzer (Hitachi 7600–020, Tokyo, Japan). Fast-
ing plasma glucose levels were assayed by the glucose
oxidase method. Hemoglobin A1c (HbA1c) was measured
by high-performance liquid chromatography with a Vari-
ant II Hemoglobin A1c analyzer (Bio-Rad Laboratories,
Hercules, CA, USA).
Statistical methods
Statistical analyses were performed using SPSS software
version 17.0 (SPSS Inc., Chicago, IL, USA). Normally
distributed data are presented as mean ± SD, whereas
skewed variables are presented as median (interquartile
range: 25th to 75th percentile). Clinical characteristics
that followed a normal distribution were compared
among groups using one-way analysis of variance with
post-hoc LSD test, while those with non-normal distri-
bution were compared using the Kruskal–Wallis test fol-
lowed by Mann–Whitney U test with Bonferroni
correction. In addition, a chi-squared test was used to
determine the differences between groups in categorical
variables. Variables that did not follow a normal distribu-
tion were log-transformed. Logistic regression analysis
was performed to identify independent factors for cer-
vical and/or intracranial plaque formation. The results of
the regression were expressed as odds ratios (OR) with
95% confidence intervals (CI). In patients with negative
finding on MRA, Spearman correlation coefficients were
employed for correlation analysis between carotid IMT
and variables. Multiple regression models were used to
explore the influence of different variables on carotid
IMT and to adjust for covariates. We calculated the
number of patients required for the study to reject the
null hypothesis 90% of the time (i.e., with a 1-tailed type
II error rate of 0.1) when r was 0.40 or higher with a 2-
tailed type I error at the 0.05 level of significance. Be-
cause this calculation led to a sample size of at least 61,
the number 63 of patients who had negative finding on
MRA was sufficient. A P value of <0.05 (two-tailed) was
considered to indicate statistical significance.
Results
Characteristics of study subjects
Subjects had a mean ± SD age of 63 ± 10 years (range:
40–86 years), mean HbA1c levels of 8.3 ± 1.7 %, and a
median (interquartile range) diabetes duration of 9.0
(5.0–13.3) years. Patients were classified according to
the presence and severity of arterial stenosis: patients
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with less than 10% stenosis in the most severely stenotic
artery (n = 105); 10–50% stenosis group: patients with
10–50% stenosis in the most severely stenotic artery
(n = 40); 51–99% stenosis group: patients with 51–99%
stenosis in the most severely stenotic artery (n = 8); no
patient had complete occlusion on MRA. The baseline
characteristics and laboratory data are shown in Table 1.
10-50% stenosis group and 51-99% stenosis group were
combined as one group (10-99% stenosis group) listed in
Table 1 because there were only 8 patients in the 51-
99% stenosis group. Compared to patients without sten-
osis, patients in <10% stenosis group and 10-99% group
were older and had significant higher TC levels. Also,
patients in 10-99% stenosis group had significantly
higher systolic blood pressure, MBG and LDL-C levels
than the other two groups (all P < 0.05). However, SDBG
and MAGE were not statistically different among the
three groups (both P > 0.05).
MRA findings
MRA findings are summarized in Table 2. Of all sub-
jects, 153 (70.8%) patients presented with at least one
cervical and/or intracranial atherosclerotic lesion. The
intracranial atherosclerotic lesions were localized mainly
at PCA, I-ICA, ACA, MCA and the cervical atheroscler-
otic lesions were localized mainly at CCA.
Logistic regression analysis of the different risk factors for
cervical and intracranial atherosclerosis
Of potential confounding risk factors, multiple logistic
regression analysis revealed that age (OR 1.115; 95.0%
CI 1.065–1.168), systolic blood pressure (OR 1.030;
95.0% CI 1.005–1.056), MBG (OR 1.245; 95.0% CI
1.000–1.549) and LDL-C (OR 1.633; 95.0% CI 0.971–
2.746) were independent factors for the presence of cer-
vical and/or intracranial lesions. The independent vari-
ables included age, sex, BMI, smoking status, diabetes
duration, HbA1c, MBG, MAGE, SDBG, blood pressure,
TG, HDL-C, LDL-C, ALT, AST, diabetes treatment, dys-
lipidemia treatment, antihypertensive treatment and as-
pirin use.
Association between carotid IMT and glycemic variability
Patients were classified into 2 groups according to MRA
results: subjects without plaque (n = 63) and subjects with
plaque (n = 153). In the former group, when carotid IMT
was tested for simple linear correlations against markers of
glucose control and nonglycemic clinical and laboratory
variables, statistically significant correlations were found
with age (r = 0.497, P < 0.001), MAGE (r = 0.365, P = 0.005)
and SDBG (r = 0.412, P = 0.001) (Figure 1). In contrast, in
subjects with atherosclerotic plaque (n = 153), carotid IMT
only correlated with age (r = 0.173, P = 0.038) among allthe markers of glycemic and nonglycemic variables and no
correlation was observed with MAGE (r = 0.089, P = 0.298)
and SDBG (r = 0.122, P = 0.147).
Next, multiple linear regression analyses were per-
formed to assess the independent effects of glycemic and
nonglycemic variables on carotid IMT in patients with-
out plaque (n = 63) (Table 3). The independent variables
included age, diabetes duration, blood pressure, HbA1c,
TG, HDL-C, LDL-C, MBG, SDBG and MAGE. Because
a strong intercorrelation was observed between MAGE
and SDBG (r = 0.813; ie, R2 =0.63) in the univariate ana-
lysis, 2 independent models were tested, 1 including the
SDBG (model 1) and 1 the MAGE (model 2). Both
SDBG (standardized β = 0.335, P = 0.005) and MAGE
(standardized β = 0.319, P = 0.010) remained significant
in stepwise regression analysis (multiple R2 = 0.314
for the model including SDBG and multiple R2 = 0.268
for the model including MAGE). The regression equa-
tions are as follows: Model 1: Carotid IMT (mm) = 0.270
mm + (0.007 mm * Age) + (0.065 mm *SDBG). Model 2:
Carotid IMT (mm) = 0.272 mm+ (0.007 mm * Age) +
(0.023 mm * MAGE).
Discussion
The present study revealed a high prevalence of cervical
and/or intracranial atherosclerotic lesions among type 2
diabetic patients as evaluated by MRA. More import-
antly, our study suggested that glycemic variability was
associated with subclinical atherosclerosis before plaque
formation because (1) SDBG and MAGE correlated with
carotid IMT only in patients without atherosclerotic
plaque; (2) conventional risk factors including elder age,
hypertension, increased MBG and increased LDL-C were
independent predictors of plaque formation; and (3)
SDBG and MAGE were not significantly different among
groups with different degrees of arterial stenosis.
Studies on glycemic variability
Chronic hyperglycemia and glycemic variability are two
major glucose characteristics of diabetes. The relationships
between chronic hyperglycemia and chronic complications
have been well-studied [16]. By contrast, the measure of
glucose variability introduces the possibility that multiple
fluctuations of blood glucose could be more dangerous
than either chronic stable hyperglycemia or a simple epi-
sode of acute hyperglycemia. Compared to chronic hyper-
glycemia, glycemic variability is poorly understood, mainly
due to limitations of glucose monitoring techniques. How-
ever, the emergence of CGM system has made it possible
to record the complete picture of 24 h glucose excursions,
and thus the glycemic variability can be accurately and
conveniently calculated. Studies on glycemic variability
have shown its association with postprandial ß-cell dys-
function [17] and glycemic variability is becoming an
Table 1 Clinical characteristics and medication use (%) at baseline of study participants
Characteristics Total Without Stenosis <10% Stenosis 10-99% Stenosis a P value
n = 216 n = 63 n = 105 n = 48
Age, y 63 (10) 57 (9) 64 (9) * 68 (10) *† <0.001
Gender, male/female 92/124 29/34 43/62 20/28 0.804
Body mass index, kg/m2 25.1 (3.8) 25.0 (4.3) 25.2 (3.5) 24.9 (3.7) 0.853
Diabetes duration, y 9.0 (5.0-13.3) 8.0 (5.0-13.0) 8.0 (4.0-14.0) 10.5 (8.5-12.8) 0.045
Systolic Blood Pressure, mmHg 135.0 (120.0-146.0) 125.0 (120.0-140.0) 135.0 (120.0-140.0) 140.0 (131.3-160.0) ‡§ <0.001
Diastolic Blood Pressure, mmHg 80.0 (75.0-85.3) 80.0 (70.0-80.0) 80.0 (70.0-85.0) 80.0 (80.0-93.8) ‡ 0.030
HbA1c, % 8.3 (1.7) 8.2 (1.7) 8.3 (1.6) 8.7 (1.9) 0.186
MBG, mmol/L 8.9 (1.9) 8.4 (1.5) 8.8 (1.9) 9.6 (2.1) *† 0.007
MAGE, mmol/l 5.6 (2.2) 5.5 (2.1) 5.7 (2.2) 5.6 (2.3) 0.800
SDBG, mmol/l 2.3 (0.8) 2.3 (0.8) 2.3 (0.8) 2.3 (0.9) 0.921
Fasting plasma glucose, mmol/l 7.8 (2.5) 7.6 (2.1) 7.7 (2.5) 8.4 (2.9) 0.266
Total cholesterol, mmol/l 4.7 (1.0) 4.4 (1.0) 4.8 (1.0) * 5.1 (1.0) * 0.002
Triglycerides, mmol/l 1.6 (1.0-2.2) 1.7 (1.0-2.4) 1.5 (1.0-2.2) 1.5 (1.1-2.2) 0.920
HDL-C, mmol/l 1.0 (0.9-1.2) 1.0 (0.9-1.2) 1.0 (0.9-1.3) 1.0 (0.9-1.2) 0.294
LDL-C, mmol/l 3.1 (0.8) 2.8 (0.8) 3.1 (0.8) 3.4 (0.8) *† 0.002
ALT, U/l 16.0 (12.0-26.0) 15.0 (12.0-27.0) 18.0 (13.0-26.5) 15.0 (11.0-26.0) 0.218
AST, U/l 18.5 (16.0-24.0) 17.0 (15.0-22.3) 20.0 (15.8-25.0) 19.0 (16.0-24.5) 0.199
BUN, mmol/l 5.5 (4.6-6.6) 5.1 (4.6-6.2) 5.7 (4.7-6.7) 5.7 (4.9-6.8) 0.141
Plasma creatinine, μmol/l 63.5 (54.0-81.0) 62.0 (53.0-76.0) 63.5 (53.0-81.0) 69.0 (54.5-84.5) 0.359
Uric acid, μmol/l 306.5 (257.0-374.3) 305.0 (265.0-393.0) 301.5 (246.0-357.8) 334.0 (267.0-384.5) 0.237
Smoking, n (%) 29 (13.4%) 14 (22.2%) 9 (8.6%) 6 (12.5%) 0.042
Medication use, n (%)
Glucose control therapy b 0.037
Oral hypoglycemic agents 68 (31.5%) 26 (41.3%) 33 (31.4%) 9 (18.8%)
Insulin 96 (44.4%) 24 (38.1%) 42 (40.0%) 30 (62.5%)
Oral hypoglycemic agents and insulin 48 (22.2%) 13 (20.6%) 27 (25.7%) 8 (16.7%)
Lipid-lowering therapy 117 (54.2%) 30 (47.6%) 60 (57.1%) 27 (56.3%) 0.430
Statins 100 (46.3%) 22 (34.9%) 51 (48.6%) 27 (56.3%)
Fibrates 17 (7.9%) 8 (12.7%) 9 (8.6%) 0 (0%)
Antihypertensive therapy 139 (64.4%) 33 (52.4%) 69 (65.7%) 37 (77.1%) 0.025
ACE inhibitors 14 (6.5%) 3 (4.8%) 11 (10.5%) 0 (0%)
Angiotensin II receptor blockers 109 (50.5%) 27 (42.9%) 49 (46.7%) 33 (68.8%)
Calcium channel blockers 57 (26.4%) 9 (14.3%) 30 (28.6%) 18 (37.5%)
Beta-blockers 15 (6.9%) 5 (7.9%) 6 (5.7%) 4 (8.3%)
Aspirin use 108 (50%) 22 (34.9%) 58 (55.2%) 28 (58.3%) 0.016
Data are mean (SD), median (25th to 75th percentile) or n (%).
a The group included 40 patients with stenosis between 10-50% and 8 patients with stenosis between 51-99%. No patient has occlusion on MRA.
b Medication use during continuous glucose monitoring period; 4 patients received diet therapy.
* P <0.05 vs without stenosis group; † P <0.05 vs <10% stenosis group; ‡ P <0.01 vs without stenosis group; § P <0.01 vs <10% stenosis group.
Abbreviations: MBG, mean blood glucose; MAGE, mean amplitude of glycemic excursions; SDBG, standard deviation of blood glucose; HDL-C, high density
lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; ACE
inhibitor, angiotensin-converting enzyme inhibitor.
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I-ICA ACA MCA PCA I-VA BA CCA SUB E-ICA ECA E-VA
Total 216 216 216 216 216 216 216 216 216 216 216
Without Stenosis 178 184 186 173 190 197 142 180 168 202 163
< 10% stenosis 28 29 15 30 17 15 68 34 38 12 48
10-50% stenosis 9 2 10 12 6 3 6 2 10 1 5
51-99% stenosis 1 1 5 1 3 1 0 0 0 1 0
Occlusion 0 0 0 0 0 0 0 0 0 0 0
Abnormal (%) 17.59 14.81 13.89 19.91 12.04 8.80 34.26 16.67 22.22 6.48 24.54
*Based on the rating of more affected side in case of bilateral vessel lesions.
Abbreviations: I-ICA, intracranial portion of the internal carotid artery; ACA, anterior cerebral artery; MCA, middle cerebral artery; PCA, posterior cerebral artery; I-VA,
intracranial vertebral artery; BA, basilar artery; CCA, common carotid artery; SUB, subclavian artery; E-ICA, extracranial portion of the internal carotid artery; ECA,
external carotid artery; E-VA, extracranial vertebral artery.
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ferent hypoglycemic treatments [18]. Moreover, glycemic
variability is also strongly correlated to HbA1c level in
elderly male patients with type 2 diabetes [19], albeit gly-
cemic variability does not provide additional prognostic
value above and beyond already recognized risk factors for
mortality during acute myocardial infarction [20]. On the
contrary, the association between intraday glycemic vari-
ability and the presence and severity of coronary artery
disease in patients with type 2 diabetes has been studied
by Su et al. [21]. So far, the relationship between glycemic
variability and diabetic macrovascluar complications
remains unclear.
Atherosclerosis detection: MRA and ultrasonography
Until now, few studies have addressed the association be-
tween glycemic variability and atherosclerosis. Chen et al.
[22] studied 36 patients with type 2 diabetes andFigure 1 Correlation between carotid IMT and glycemic variability in
deviation of blood glucose (SDBG) was positively correlated to carotid IMT
excursion (MAGE) was positively correlated to carotid IMT (r = 0.365, P = 0.0demonstrated that carotid IMT was correlated with
MAGE. However, the authors used ultrasound to detect
both preclinical atherosclerosis and the plaque formation.
As a quantitative variable, carotid IMT is a feasible tech-
nique for evaluating subclinical atherosclerosis but may
have several limitations when defining plaque, including
inability to visualize intracranial vessels, difficulties in
detecting near-total occlusion, and high reliance on oper-
ator skill [23,24]. For the Chinese population, assessing
intracranial vessels is particularly important because East
Asians were reported to be significantly more susceptible
to intracranial atherosclerotic lesions than are Caucasians
[25]. Thus, using ultrasound assessment alone, patients
with only intracranial plaque cannot be accurately
detected. Therefore, in terms of defining the presence of
plaque, we evaluated both cervical and intracranial vessels
using CEMRA and 3D-TOF-MRA. CEMRA is more spe-
cific and can provide additional diagnostic informationsubjects without atherosclerotic lesion on MRA. (A) The standard
(r = 0.412, P = 0.001) (n = 63). (B) The mean amplitude of glycemic
05) (n = 63).
Table 3 Results of stepwise regression analysis with carotid IMT as the dependent variable in patients without lesions
on MRA (n = 63)
Explanatory variable Standardized Regression
Coefficient
t P Value Adjusted R2 of
the Model
Model 1 0.314
Age 0.415 3.609 0.001
SDBG 0.335 2.909 0.005
Model 2 0.268
Age 0.413 3.470 0.001
MAGE 0.319 2.682 0.010
Abbreviations: SDBG, standard deviation of blood glucose; MAGE, mean amplitude of glycemic excursions.
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plications of conventional angiography in assessing cer-
vical vessels [7]. 3D-TOF-MRA allows more accurate
evaluation of intracranial steno-occlusive disease among
the noninvasive imaging techniques [8]. In addition, MRA
technology depends less on the operator and is associated
with lower inter-observer variability than is ultrasonog-
raphy. To our knowledge, the present study is the first to
use both MRA and ultrasonography to evaluate different
stages of atherosclerosis in order to explore a potential re-
lationship with glycemic variability.
Glucose fluctuation and atherosclerosis
Using the CGM system we report that, in diabetic patients
without atherosclerotic lesions, SDBG and MAGE were
significantly related to carotid IMT, raising the intriguing
possibility that glycemic variability plays a key role in the
subclinical stage of atherosclerosis. Our results are partly
in agreement with several in vitro and epidemiological
studies suggesting that glucose fluctuation can harm the
arterial wall through oxidative stress and/or endothelial
dysfunction [4,5]. Meanwhile, as a major contributor to
glycemic variability, postprandial blood glucose, especially
the acute hyperglycemia after a meal or glucose load, was
found to be strongly associated with endothelial function,
carotid IMT and cardiovascular diseases [26,27]. Suzuki
et al. [28] found the attenuation of brachial artery flow-
mediated dilation (FMD) in the postprandial state was
correlated with postprandial glucose fluctuation and the
postprandial serum insulin level in individuals with nor-
mal glucose tolerance. Esposito, et al. [29] found that
incremental glucose peak, the maximal incremental in-
crease in blood glucose obtained at any point after the
meal, was correlated with carotid IMT, suggesting post-
prandial glucose is involved in the process of subclinical
atherosclerosis. In addition, the management of postpran-
dial hyperglycemia in type 2 diabetes is related to regres-
sion of atherosclerosis [30]. For example, Mitiglinide, a
short-acting insulinotropic agent to ameliorate postpran-
dial hyperglycemia, was shown to reduce excess oxidative
stress and inflammation [31].Hypothesis
We speculate that endothelial dysfunction may underlie
the association between glycemic variability and subclin-
ical atherosclerosis. Although atherosclerosis is com-
monly described as the presence of plaque obstructing
the lumen of the conduit arteries, endothelial dysfunc-
tion is regarded as the initial step in the development of
atherosclerosis and can be observed preceding structural
atherosclerotic changes in the vascular wall or ultrasonic
evidence of plaque [32,33]. Hashimoto et al. [34] studied
the correlation between carotid IMT and FMD of the
brachial artery, and found that FMD was related to ca-
rotid IMT only in subjects without overt atherosclerosis,
which suggested that endothelial dysfunction correlates
with carotid IMT before the development of macro-
scopic anatomic atherosclerosis. Therefore, because gly-
cemic variability was reported to be associated with
endothelial dysfunction [5], and endothelial dysfunction,
the initial process of atherosclerosis, seems to be corre-
lated with carotid IMT in subjects without overt plaque,
we speculate that the association between larger gly-
cemic variability and increased carotid IMT is most
likely due to the mechanism of endothelial dysfunction.
Unfortunately, we did not measure any marker to sub-
stantiate our assumption in this study. Further studies
need to be carried out to elucidate the mechanism.
Clinical significance
Our study revealed that glycemic variability is related to
subclinical atherosclerosis before the plaque is formed. On
the other hand, we identified conventional risk factors such
as age, hypertension, dyslipidemia and increased mean
blood glucose level as important independent predictive
factors for atherosclerotic plaque formation instead of gly-
cemic variability. Indeed, substantial evidence suggests that
chronic hyperglycemia plays a specific role in atheroscler-
osis progression in patients with diabetes [35]. Needless to
say, the combination of antihyperglycemic treatment with
lipid-lowering, antihypertensive, and antiplatelet therapy is
currently regarded as the primary strategy for reducing the
burden of macrovascular complications in diabetes [36-38].
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http://www.cardiab.com/content/12/1/15In light of these results, we highlight the importance of
adopting a multifactorial approach to the prevention of
macrovascular disease in type 2 diabetic patients. Identify-
ing patients at risk for atherosclerotic lesions using MRA
technique may be a priority. In patients with lesions, strict
blood-pressure control, lipid-lowering therapy should be
emphasized. For those who have negative finding by
MRA, early initiation of glycemic variability management
is likely to be beneficial in preventing the development
and progression of atherosclerosis.Limitations
The present study has some limitations. First, even
though all the included patients received stable thera-
peutic regimen for 3 months before the study, a 2-day
CGM profile may not sufficiently reflect the actual gly-
cemic condition over a longer period. Second, because
this was a cross-sectional study, our conclusions are
based essentially only on correlation analysis. A larger
prospective investigation is required in order to further
demonstrate the role that glycemic variability plays in
the process of atherosclerosis. Third, we did not assess
the relationship between endothelial dysfunction and
glycemic variability in the study to substantiate our
results. Further studies are needed in the future.Conclusions
In conclusion, glycemic variability is associated with sub-
clinical atherosclerosis in type 2 diabetic patients. Further
studies will be necessary to clarify the role of glucose vari-
ability as a potential contributory factor to the complex
processes of atherosclerosis development.
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